News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Ruben Mesa: Most active combination for MF to date
Ruben Mesa/patientpower.info
Jun 18, 2024, 03:30

Ruben Mesa: Most active combination for MF to date

Ruben Mesa shared on LinkedIn:

“Honored to be a Co-Investigator of important Pelabresib plus RUX 1L vs RUX Phase III trial presented as dual abstracts at EHA2024 by Raajit Rampal demonstrating impact of PELA/RUX on fibrosis, erythroid progenitors, VAF, splenomegaly and most symptoms. Most active combination for MF to date!”

Ruben Mesa: Most active combination for MF to date

Source: Ruben Mesa/LinkedIn

cancer EHA2024 OncoDaily Oncology Pelabresib plus RUX 1L Phase III trial Raajit Rampal Ruben Mesa
Special Coverage
Science
Feb 22, 2025, 16:16
Angela Lamarca: Current management of advanced HCC
Blog
Feb 22, 2025, 16:04
Eric Lehrer: Role of WBRT in multifocal LGG
Science
Feb 22, 2025, 16:00
Malak Alharbi: Diagnostic and therapeutic challenges in PRCA secondary to SMM
Blog
Feb 22, 2025, 15:54
Patrick Forde: Great day for lung cancer care
Science
Feb 22, 2025, 15:48
Shankar Siva: Whats new in stage IV cancer?
Science
Feb 22, 2025, 15:33
Updated ESMO Clinical Practice Guideline on Hepatocellular Carcinoma
Science
Feb 22, 2025, 15:14
Erman Akkus: Stage specific characterization of early-onset colorectal cancer
Blog
Feb 22, 2025, 15:04
John Gordon: Successful CAR Tcell Therapy - "It's a Bug's Life"
Blog
Feb 22, 2025, 14:43
Giannis Mountzios: How active ADCs against oncogene-addicted NSCLC?
Science
Feb 22, 2025, 14:10
Yan Leyfman: Advancing CAR T-Cell Therapy - Off-the-Shelf Allogeneic Approach
Science
Feb 22, 2025, 13:28
Elvina Almuradova: Immunotherapy for HPV-Associated Cancers
Opinion
Feb 22, 2025, 13:10
Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding